University of Leicester
Browse
Systematic Review_updated_no track changes.pdf (358.07 kB)

Prevalence of comorbidities and their association with mortality in patients with COVID‐19: A Systematic Review and Meta‐analysis

Download (358.07 kB)
journal contribution
posted on 2020-06-26, 14:22 authored by Awadhesh Kumar Singh, Clare L Gillies, Ritu Singh, Akriti Singh, Yogini Chudasama, Briana Coles, Sam Seidu, Francesco Zaccardi, Melanie J Davies, Kamlesh Khunti
Aims
COVID‐19 is a global pandemic that as of the 4th May has registered over 3 585 711 confirmed cases and 248 780 deaths. This review aims to estimate the prevalence of both cardiometabolic and other co‐morbidities in patients with COVID‐19 infection, and to estimate the increased risk of severity and mortality in people with co‐morbidities.

Materials and Methods
Medline, Scopus and the World Health Organisation (WHO) website for Global research on COVID‐19 were searched from January 2019 up to April 23, 2020. Study inclusion was restricted to English language publications, original articles that reported prevalence of co‐morbidities in individuals with COVID‐19 disease, and case‐series >10 patients. 18 studies were selected for inclusion. Data were analysed using random effects meta‐analysis models.

Results
Eighteen studies with a total of 14 558 individuals were identified. The pooled prevalence for co‐morbidities in patients with COVID‐19 disease was 22.9% (95% CI: 15.8 to 29.9) for hypertension; 11.5% (9.7 to 13.4) for diabetes; and 9.7% (6.8 to 12.6) for cardiovascular disease (CVD). For chronic obstructive pulmonary disease (COPD), chronic kidney disease (CKD), cerebrovascular disease, and cancer, the pooled prevalences were all less than 4%. With the exception of cerebrovascular disease, all other co‐morbidities had a significantly increased risk for having severe COVID‐19. In addition, the risk of mortality was significantly increased in individuals with CVD, COPD, CKD, cerebrovascular disease, and cancer.

Conclusions
In individuals with COVID‐19, the presence of co‐morbidities (both cardiometabolic and other) is associated with a higher risk of severe COVID‐19 and mortality. These findings have important implications for the public health with regards to risk stratification and future planning.

History

Citation

Diabetes, Obesity and Metabolism: a journal of pharmacology and therapeutics, 2020, https://doi.org/10.1111/dom.14124

Author affiliation

Leicester Real World Evidence Unit, Leicester Diabetes Centre, University of Leicester

Version

  • AM (Accepted Manuscript)

Published in

Diabetes, Obesity and Metabolism: a journal of pharmacology and therapeutics

Publisher

Wiley

issn

1462-8902

eissn

1463-1326

Acceptance date

2020-06-23

Copyright date

2020

Available date

2021-06-23

Language

en

Publisher version

https://dom-pubs.onlinelibrary.wiley.com/doi/10.1111/dom.14124

Usage metrics

    University of Leicester Publications

    Categories

    Exports

    RefWorks
    BibTeX
    Ref. manager
    Endnote
    DataCite
    NLM
    DC